ArticleFrontiers in genetics2025
Dopamine D2 receptor gene Taq 1A polymorphism: genetic architecture in Indian population and comparison to global populations.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Dopamine receptor D2 (DRD2) gene has been investigated as a candidate gene in several psychiatric and neurological disorders involving dopaminergic systems. Multiple polymorphisms have been reported in the DRD2 gene, where the DRD2 Taq1A is most widely studied and is reported to contribute to the development of several diseases/disorders. The objective was to study the DRD2 Taq1A polymorphism in the Indian population and compare it with the reported global frequency. Methods: The DRD2 Taq1A polymorphism was genotyped using PCR-RFLP from 400 unrelated human blood samples. In addition, a literature search on the DRD2 Taq1A polymorphism has also been conducted from 1990 to 2025. All the data obtained was grouped according to the continent as a unit to get the distribution information of the DRD2 Taq1A genotypes and alleles in healthy populations of all six continents. This was accomplished for the comparison of frequency obtained in this study with the overall geographical distribution of the DRD2 Taq1A allele reported from other parts of the world. Results: In the total 400 samples analyzed, the TT genotype and T allele frequencies were 15% and 43%, respectively. Data from 136 studies from different continents were extracted and compared with the present study. The highest T allele frequency was observed in the Asia (0.35), followed by South America (0.33) and the lowest frequencies occur in Europe and Australia (0.19). Pattern of frequencies represented by the Indians is consistent to Asia and close to South America. The result show a high frequency of CT genotype and T allele in the study population, closely resembling the patterns observed in Mexicans. This study highlights the genetic diversity within Indian subpopulations and underscores the need for cautious interpretation of population genetic data. Conclusion: The present study observed a T allele frequency of 43%, comparable with the Asian population. In the comparison study, the T allele frequency in Global, Asian, Indian, and present studies was calculated as 26%, 35%, 33%, and 43%, respectively. This geographical gradient is clinically important in determination of the risk assessment which might be included in prevention strategies for psychiatric disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.